<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01668446</url>
  </required_header>
  <id_info>
    <org_study_id>radvin123</org_study_id>
    <secondary_id>rad123</secondary_id>
    <secondary_id>rad123</secondary_id>
    <nct_id>NCT01668446</nct_id>
  </id_info>
  <brief_title>Effect of Adding Sildenafil to Protocol of Endometrial Preparation in Outcome of Frozen-thawed Embryo Transfer Cycles</brief_title>
  <acronym>sildenafil</acronym>
  <official_title>Effect of Adding Sildenafil to Protocol of Endometrial Preparation in Outcome of Frozen-thawed Embryo Transfer Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>farzaneh hojjat</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Razieh dehghani firouzabadi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Robab davar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shahid Sadoughi University of Medical Sciences and Health Services</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The target of this study was an estimate the result of sildenafil on ultrasonographic
      endometrial thickness, endometrial pattern investigation estrogen level on the day of
      progesterone administration, Implantation rate and chemical pregnancy rate in frozen embryo
      transfer cycles .
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>estimate the result of sildenafil on ultrasonographic endometrial thickness</measure>
    <time_frame>between 2009-2011 (up to 2 years)</time_frame>
    <description>Assays:
Day 13 of menstrual cycle endometrial thickness estimated with Transvaginal ultrasonographic(arranged in a series every other day), evaluations were performed by a single investigator, If the endometrial thickness is more than 8mm progesterone injected 100 mg intramuscular and Estrogen, progesterone and lh measured in blood sample then after three days embryo transferred.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>estimate the result of sildenafil on Implantation rate and chemical pregnancy rate in frozen embryo transfer cycles .</measure>
    <time_frame>between 2009-2011 (up to 2 years)</time_frame>
    <description>Implantation rate was higher in sildenafil Group but not significant chemical pregnancy rates were higher in sildenafil Group but not significant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Endometrial Preparation</condition>
  <condition>Frozen Embryo Transfer</condition>
  <arm_group>
    <arm_group_label>sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One of two group to prepare the endometrium give estradiol by step up method with menstruation.
From first to fourth day of menstrual cycle, estradiol valerat tablet 2 mg daily From Fifth to eighth day of menstrual cycle, estradiol valerat tablet 4 mg daily From Ninth to twelfth day of menstrual , estradiol valerat tablet 6 mg daily The second group in addition to the above treatment protocol from First day of cycle until day of starting progesterone will be given sildenafil tablets(50 mg) daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sildenafil and estradiol valerat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One of two group to prepare the endometrium give estradiol by step up method with menstruation.
From first to fourth day of menstrual cycle, estradiol valerat tablet 2 mg daily From Fifth to eighth day of menstrual cycle, estradiol valerat tablet 4 mg daily From Ninth to twelfth day of menstrual , estradiol valerat tablet 6 mg daily The second group in addition to the above treatment protocol from First day of cycle until day of starting progesterone will be given sildenafil tablets(50 mg) daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>sildenafil tablets(50 mg) daily</description>
    <arm_group_label>sildenafil</arm_group_label>
    <arm_group_label>Sildenafil and estradiol valerat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estradiol valerat</intervention_name>
    <arm_group_label>Sildenafil and estradiol valerat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women &gt; 40 years old,

          -  history of endocrine disease

          -  Hysteroscopic surgery

          -  cardiovascular, renal and liver disease

          -  hypotension( blood pressure &lt; 90/50)

          -  history of stroke or myocardial infarction

          -  use of alcohol or substance

        Exclusion Criteria:

        A total of 80 patients with antecedent of poor endometrial response and had frozen embryo
        included in this study all women must to be &lt; 40 years old,

          -  no history of endocrine disease,

          -  no Hysteroscopic surgery, had a high quality embryos no cardiovascular,

          -  renal and liver disease and

          -  no hypotension (blood pressure &lt; 90/50) or

          -  history of stroke or myocardial infarction and

          -  don't use of alcohol or substance Patients with these conditions enter this study and
             based on randomized tables are divided in two groups.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>farzaneh hojjat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics and Gynecology, Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Science, Bouali Ave. Safaieh, Yazd,Iran.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Farzaneh Hojjat</name>
      <address>
        <city>Yazd</city>
        <zip>8916878466</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2012</study_first_submitted>
  <study_first_submitted_qc>August 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2012</study_first_posted>
  <last_update_submitted>September 11, 2012</last_update_submitted>
  <last_update_submitted_qc>September 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Sadoughi University of Medical Sciences and Health Services</investigator_affiliation>
    <investigator_full_name>farzaneh hojjat</investigator_full_name>
    <investigator_title>Farzaneh hojjat MD</investigator_title>
  </responsible_party>
  <keyword>Sildenafil</keyword>
  <keyword>Endometrial thickness</keyword>
  <keyword>Frozen embryo transfer</keyword>
  <keyword>ultrasonographic endometrial thickness</keyword>
  <keyword>endometrial pattern</keyword>
  <keyword>Implantation rate</keyword>
  <keyword>chemical pregnancy rate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

